

<p>Substitute for Form 1449 A & B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				<i>Complete if Known</i>	
				Application Number	Unknown
				Confirmation Number	Unknown
				Filing Date	April 25, 2006
				First Named Inventor	Yeon-Soo KIM
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	1	Attorney Docket Number	Q94261

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				Translation ⁶
		J. PAN et al., "Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF- κ B", <i>Journal of General Virology</i> , Vol. 82, No. 1, 2001, pp. 171-182				
		F. SU et al., "Role of NF- κ B and Myc proteins in apoptosis induced by hepatitis B virus HBx protein", <i>Journal of Virology</i> , Vol. 75, No. 1, 2001, pp. 215-225				
		A. ARLT et al., "Inhibition of NF- κ B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin", <i>Oncogene</i> , Vol. 20, No. 7, Feb. 2001, pp. 859-868				
		N. KATO et al., "Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer", <i>Hepatology</i> , Vol. 32, No. 2, 2000, pp. 405-412				
		S. MUERKOSTER et al., "Usage of NF- κ B inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer", <i>Int. J. Cancer</i> , Vol. 104, No. 4, Apr. 2003, pp. 469-476				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.